Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia.
Some recent reports show that schizophrenia is accompanied by changes in lymphocyte activity. This study investigated the activity of monocytes by determining their release of interleukin- 1 beta (IL- 1 beta) and tumor necrosis factor-alpha (TNF-alpha). Monocytes were immunomagnetically isolated from the peripheral blood of schizophrenic patients before and after neuroleptic medication and stimulated by lipopolisaccharide (LPS) in vitro. The monocytes of schizophrenic patients released significantly higher amounts of IL- 1 beta and TNF-alpha than those of healthy controls. Treatment with the typical neuroleptics haloperidol and perazine decreased the release of IL- 1 beta and TNF-alpha to the control levels. The study has shown that the activity of monocytes is increased in schizophrenia and that neuroleptic treatment normalizes this activity.
Kowalski
J
J
Department of Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Blada
P
P
Kucia
K
K
Madej
A
A
Herman
Z S
ZS
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006220:Haloperidol / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects; D010464:Perazine / Q000494:pharmacology* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000378:metabolism*
D014150:Antipsychotic Agents; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D010464:Perazine; D006220:Haloperidol